FDA approves Susvimo for diabetic macular edema

The U.S. Food and Drug Administration has approved Genentech’s Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup